The Vaxzevria COVID-19 vaccine – benefit-risk ratio during clinical development

For a while, AstraZeneca/University of Oxford’s product was the front-runner in the race to develop a COVID-19 vaccine. However, during their Phase 3 trial, one subject developed transverse myelitis (spinal inflammation), a potentially serious adverse reaction.